Late Onset Alzheimer's Disease

NCT ID: NCT05010603

Last Updated: 2025-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-15

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to focus on the genetic influences on Alzheimer's disease (AD) risk. Specifically, the investigators hypothesize that one or more genes, other than the previously identified susceptibility gene apolipoprotein-E (APOE), or the 3 genes associated with early-onset familial AD, presenilin-1 (PS-1), presenilin-2 (PS-2) or B-amyloid precursor protein (APP), increase the risk of AD in families with multiple individuals affected with AD. The investigators propose to test this hypothesis by performing genetic linkage analysis in order to detect the chromosomal location of genes that may increase the risk of Alzheimer's disease. In addition, the investigators will study genes known to increase the risk of Alzheimer's disease and other related disorders such as early onset AD, Pick disease, corticobasal degeneration, progressive supranuclear palsy, and familial frontotemporal dementia with parkinsonism and Lewy Body Dementia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Families with a history of Alzheimer's Disease

Families with two or more family members affected with Alzheimer's Disease

Blood Draw

Intervention Type GENETIC

Collection of blood samples for genetic testing

Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test

Intervention Type OTHER

Memory Test

Un-related, non-demented controls

Un-related, non-demented healthy controls over age 55

Blood Draw

Intervention Type GENETIC

Collection of blood samples for genetic testing

Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test

Intervention Type OTHER

Memory Test

Individuals with Dementia (Alzheimer's Disease)

Individuals with dementia over the age of 65

Blood Draw

Intervention Type GENETIC

Collection of blood samples for genetic testing

Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test

Intervention Type OTHER

Memory Test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Draw

Collection of blood samples for genetic testing

Intervention Type GENETIC

Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test

Memory Test

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases.
* a living sibling with probable or possible AD;
* a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older);
* participants in the proband's generation with an identified companion serving as an informant;
* participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.

Exclusion Criteria

* failure to identify an appropriate informant;
* uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder;
* discovery of additional diagnosis that could account for the clinical manifestations;
* unwillingness to participate;
* failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD);
* participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

Columbia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard P. Mayeux, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Washington

Washington D.C., District of Columbia, United States

Site Status RECRUITING

University of Miami

Miami, Florida, United States

Site Status RECRUITING

Rush University

Aurora, Illinois, United States

Site Status RECRUITING

Indiana University

Bloomington, Indiana, United States

Site Status RECRUITING

NCRAD at Indiana University

Indianapolis, Indiana, United States

Site Status RECRUITING

Mayo Clinic

Rochester, Minnesota, United States

Site Status RECRUITING

Joanne Norton

St Louis, Missouri, United States

Site Status RECRUITING

Columbia University Irving Medical Center

New York, New York, United States

Site Status RECRUITING

North Carolina State University

Raleigh, North Carolina, United States

Site Status RECRUITING

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status RECRUITING

University of Texas Southwestern

Dallas, Texas, United States

Site Status RECRUITING

University of Washington

Seattle, Washington, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dolly Reyes-Dumeyer

Role: CONTACT

212-305-5953

Amanda Chan

Role: CONTACT

917-696-3082

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sarah Payne

Role: primary

Larry Deon

Role: primary

Corey Woods

Role: primary

Kelly Farber

Role: primary

Kelly Farber

Role: primary

Christine Hanzel

Role: primary

Joanne Norton

Role: primary

Dolly Reyes-Dumeyer

Role: primary

212-305-5953

Amanda Chan

Role: backup

917-696-3082

Takiyah Starks

Role: primary

Elise Weamer

Role: primary

Amy Browning

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

5U24AG056270

Identifier Type: NIH

Identifier Source: secondary_id

View Link

AAAP0479

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Decoding Your Diet (DYD)
NCT05904639 UNKNOWN EARLY_PHASE1